Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.
Zhibo GaiTing GuiIrina AlecuMuseer A LoneThorsten HornemannQingfa ChenMichele VisentinChristian HillerStephanie HauslerGerd A Kullak-UblickPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
Our study identifies FXR-Cyp4f as a novel regulatory pathway for 1-deoxysphingolipid metabolism. FXR activation represents a promising therapeutic strategy for patients with metabolic syndrome and NAFLD.